Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11473 posts found.

NICE does not recommend icosapent ethyl for prevention of cardiovascular events

March 28, 2022 Sales and Marketing

NICE has published further draft guidance for public consultation which does not recommend VAZKEPA (icosapent ethyl) for reducing the risk …
News

FDA approve oral solution for rare childhood epilepsy

March 28, 2022 Sales and Marketing

UCB has announced that FINTEPLA® (fenfluramine) oral solution CIV has been approved by the FDA for the treatment of seizures …
News

EMA review first novel gene therapy candidate for haemophilia B

March 28, 2022 Sales and Marketing

CSL Behring has today announced that the EMA has accepted the Marketing Authorising Application for etranacogene dezaparvovec (EtranaDez), under its …
News

Pregnant women to receive life-saving pre-eclampsia check on NHS

March 28, 2022 Sales and Marketing

A life-saving blood test that can help diagnose suspected preterm pre-eclampsia has been recommended by NICE, and this is to …
News
guy_photo_2022_002

Ipsen appoints Guy Oliver as General Manager, UK & Ireland

March 21, 2022 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Ipsen have announced the appointment of Guy Oliver as General Manager of its UK and Ireland affiliate. Guy brings a …
Appointment

FDA approval for first in class immunotherapy for advanced melanoma

March 21, 2022 Sales and Marketing

The FDA has approved Bristol-Myers Squibb’s Opdualag (nivolumab and relatlimab-rmbw), the first drug in a new class of cancer immunotherapies, …
News

Spring COVID-19 booster launches for over-75s and high risk in England

March 21, 2022 Sales and Marketing

Those aged 75 and over, alongside residents in care homes and those with weakened immune systems, can now book an …
News

UCLA’s HIV prevention and treatment centre receives $7.5 million NIH grant

March 21, 2022 Sales and Marketing

The National Institute of Mental Health has renewed its support for UCLA’s collaborative Centre for HIV Identification, Prevention and Treatment …
News

Merck’s Keytruda delivers reduced risk of death in adjuvant NSCLC

March 21, 2022 Sales and Marketing

Merck has announced positive results from its Phase III trial into Keytruda for non-small cell lung cancer. The KEYNOTE-091 study …
News

CanSinoBIO’s Convidecia effective as booster against Omicron

March 14, 2022 Sales and Marketing

According to an academic paper on the efficacy of CanSinoBIO’s recombinant COVID-19 vaccine, published on medRxiv, the vaccine is effective …
News
e-6olmfwuay74lr

UK Health Secretary: rise in COVID-19 cases ‘expected’

March 14, 2022 Sales and Marketing

A surge in COVID-19 cases was to be “expected”, following the ease of pandemic restrictions in England, insisted UK Health …
News

First and only approved medicine in US targeting BRCA mutations in early breast cancer

March 14, 2022 Sales and Marketing

LYNPARZA® (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk …
News

Malaysia to receive Pfizer’s COVID-19 pills in two weeks, says Health Minister

March 7, 2022 Sales and Marketing

Khairy Jamaluddin, Health Minister of Malaysia, has shared that the country expects to receive its first shipment of Pfizer’s oral …
News

HUTCHMED receives $15 million to begin Phase III study of lung cancer treatment

March 7, 2022 Sales and Marketing

HUTCHMED has received $15 million from AstraZeneca, for the initiation of start-up activities for SAFFRON, the first global Phase III …
News

AbbVie acquires Syndesi Therapeutics

March 7, 2022 Sales and Marketing

Syndesi Therapeutics has been acquired by AbbVie in a deal worth a potential $1 billion.Syndesi was created in 2018 as …
News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024